An Update on Osteoporosis Pathogenesis, Diagnosis, and Treatment
An Update on Osteoporosis Pathogenesis, Diagnosis, and Treatment is an on-demand webcast CME activity. Osteoporosis is a serious health problem that is increasing with the growth of the aging population. Left untreated, patients with osteoporosis experience considerable morbidity and increased mortality, and their care exacts a large economic burden on the health care system. Although regularly updated clinical guidelines, risk assessment tools, and effective pharmacologic agents are available for the prevention and treatment of osteoporosis, data indicate that patients are not receiving the recommended level of care. In fact, the percentage of patients receiving osteoporosis treatment has declined in recent years even in those with hip fractures.
Meanwhile, the field of osteoporosis has seen many advances, including new insights into bone metabolism, new imaging techniques, new drugs with novel mechanisms of action, and new approaches to patient selection and management.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with osteoporosis.
Upon completion of this activity, participants will be better able to do the following:
Describe advances in the understanding of bone biology and metabolism
Discuss emerging imaging techniques for the diagnosis of osteoporosis
Analyze the safety and efficacy of current and emerging treatments for osteoporosis
Michael McClung, MD, FACP (Moderator)
Roland Baron, DDS, PhD
Mary Bouxsein, PhD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Relationship Identified With:
Michael McClung, MD, FACP
Consultant/Advisor: Amgen Inc; Merck & Co., Inc; Radius Health Inc.
Speakers' Bureau: Amgen Inc
Roland Baron, DDS, PhD
Consultant/Advisor: Amgen Inc; Bone Therapeutics; DAIICHI SANKYO COMPANY, LIMITED; Eli Lilly and Company; Merck & Co., Inc; Osteo-Pharma BV; Radius Health Inc.
Speakers' Bureau: Amgen Inc; Merck & Co., Inc
Stock Owner: Amgen Inc; Bone Therapeutics; Radius Health Inc.
Grant/Research Support: Merck & Co., Inc
Employment Affiliation: Bone Therapeutics
Mary Bouxsein, PhD
Consultant/Advisor: Eli Lilly and Company; Merck & Co., Inc; Radius Health Inc.
Grant/Research Support: Amgen Inc; Merck & Co., Inc
Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This CME activity has been peer-reviewed by Bone.
This activity has been supported by an independent educational grant from Merck & Co., Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education; Miller Medical Communications, LLC; and Merck & Co., Inc, do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician